CMS Deputy Administrator Conway's appearance at the Finance Committee prompted questions about a theoretical next demonstration project while members challenged the project currently on the table; Conway suggested some ‘adjustments’ are coming to the proposed Part B demo.

Drug pricing and government oversight were raised as critical issues for the industry in panels, presentations and conversations throughout the BIO CEO & Investor conference, with opinions varying on how much of a threat it could be.

Administration’s proposal to increase Medicaid leverage via more “unified” approach adds another idea to drug-pricing debates, though it would require legislation.